110
Participants
Start Date
July 31, 2020
Primary Completion Date
September 1, 2023
Study Completion Date
October 31, 2023
STA363 containing 90 mg (60 mg/mL) lactic acid
STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
STA363 containing 180 mg (120 mg/mL) lactic acid
STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
Placebo
Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
Alrijne Ziekenhuis Leiderdorp, Leiderdorp
Rijnstate Hospital Anesthesiology and Pain, Velp
Belgorod Regional Clinical Hospital of Saint Joasaph, Belgorod
Regional Clinical Hospital #3, Chelyabinsk
Kirov State Medical University, Kirov
Ochapovsky Regional Clinical Hospital #1, Krasnodar
Krasnoyarsk Interdistrict Clinical Emergency Hospital, Krasnoyarsk
Siberian Research Clinical Center, Krasnoyarsk
Privolzhsky Research Medical University, Nizhny Novgorod
Bekhterev Psychiatry and Neurology Center, Saint Petersburg
LLC MART, Saint Petersburg
Smolensk Regional Clinical Hospital, Smolensk
Tula Regional Clinical Hospital, Tula
Hospital Quirónsalud Córdoba, Córdoba
Complejo Hospitalario Ruber Juan Bravo, Madrid
Hm Puerta Del Sur, Móstoles
Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón
Lead Sponsor
Stayble Therapeutics
INDUSTRY